Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + APG-157
- Development stage
- Preclinical
- Lead developer
- Aveta Biomics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
temozolomide + APG-157 is a combination therapeutic under investigation for the treatment of recurrent glioblastoma. **Temozolomide** is an oral alkylating agent that damages DNA in cancer cells, leading to cell death. **APG-157** is a first-in-class botanical drug made up of plant-derived compounds (including curcumin) that acts by inducing selective apoptosis in cancer cells and reprogramming the immune environment, including reducing inflammation and attracting T-cells to the tumor microenvironment. APG-157 is administered as an oral lozenge and shows low toxicity. The combination has been explored in expanded access and clinical trial settings for its potential to improve survival and quality of life in patients with advanced brain cancers, specifically glioblastoma. The combination therapy has not shown significant adverse effects, but evidence is limited and further studies are needed.[5][3]
- Brand names
- temozolomide + APG-157
- Other names
- temozolomide + APG-157
02
Targets
DNAORM1 (Alpha-1-acid glycoprotein 1)
Beyond the preview
Go deeper on temozolomide + APG-157.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + APG-157.